A single-dose vaccine for COVID-19 that amplifies its own effectiveness
Evaluation of iDMV-1.0: A Single Dose Self-Amplifying Vaccine for SARS-CoV-2
This study is testing a new one-dose vaccine called iDMV-1.0 that helps your body fight off COVID-19 by making a part of the virus, aiming to give you long-lasting protection without needing extra shots, especially for people in places where getting vaccines can be tough.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project ID | NIH-10894875 on NIH RePORTER |
What this research studies
This research focuses on developing a novel self-amplifying mRNA vaccine called iDMV-1.0 for SARS-CoV-2, which aims to provide long-lasting immunity with just one dose. The vaccine is designed to produce the Spike protein of the virus within the body, enhancing the immune response without the need for multiple booster shots. By utilizing a unique RNA structure, this vaccine could simplify vaccination logistics, especially in low- and middle-income countries where access to healthcare is limited. The research will assess the vaccine's effectiveness in preclinical studies using mice to evaluate its potential for human use.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals in low- and middle-income countries who have limited access to multiple vaccine doses.
Not a fit: Patients who have already received multiple doses of existing COVID-19 vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more accessible and efficient COVID-19 vaccination strategy, potentially increasing global vaccination rates.
How similar studies have performed: Other research has shown promise with self-amplifying mRNA vaccines, indicating potential for success with this novel approach.
Where this research is happening
Burlington, United States
- University of Vermont & St Agric College — Burlington, United States (Active)
Researchers
- Principal investigator: Majumdar, Devdoot — University of Vermont & St Agric College
- Study coordinator: Majumdar, Devdoot
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.